AcquisitionsAug 7, 2026, 07:06 AM
Gyre Therapeutics Q2 Revenue $29.1M; F351 NDA Accepted; Cullgen Acquired
AI Summary
Gyre Therapeutics announced its Q2 2026 financial results, reporting $29.1 million in revenue and a GAAP basic EPS of $(0.12), while affirming its full-year 2026 revenue guidance. The company highlighted the significant strategic closing of the Cullgen Inc. acquisition, valued at approximately $300 million, which expanded its pipeline into cancer and inflammatory diseases. Additionally, China's CDE accepted the New Drug Application (NDA) for F351 (hydronidone) for CHB-induced liver fibrosis, marking a key regulatory milestone.
Key Highlights
- Cullgen Inc. acquisition closed in Q2 2026 for approximately $300 million in an all-stock transaction.
- NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026.
- Q2 2026 revenue was $29.1 million, a 2% decrease from $29.7 million in Q2 2025.
- Q2 2026 GAAP basic EPS was $(0.12), compared to $(0.02) in Q2 2025.
- Full-year 2026 revenue guidance of $100.5 million to $111.0 million was affirmed.
- ETUARYTM sales increased to $28.0 million in Q2 2026 from $23.5 million in Q2 2025.
- Net loss for Q2 2026 was $14.3 million, compared to a net loss of $2.2 million in Q2 2025.
- Cash and cash equivalents totaled $103.2 million as of June 30, 2026.
Price Impact
More from GYRE